Cancer Network
Spotlight
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer UpdatesCancerNetwork® Inaugural Face-OffContemporary Concepts in Hematologic OncologyInsights from Experts at Mayo Clinic on Translating Evidence to Clinical PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast CancerReal-World Evidence in NSCLC Guides Clinical Decisions Targeting NSCLC with Uncommon EGFR Mutations
Clinical
View MoreAcute Myeloid LeukemiaBrain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
News
Clinical TopicsIntegrative CareGlobal BulletinAll NewsApproval Alert
Media
2 Minute DrillAround the PracticeAwareness MonthBetween the LinesClinical ConsultExpert InterviewsFace OffMedical World NewsMorning RoundsOncViewPodcastsReadout 360Year in Review
Conferences
Publications
All JournalsFor AuthorsTumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary ConceptsInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Subscribe
eNewsletterPrint Subscription

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2023 MJH Life Sciences and Cancer Network. All rights reserved.

Advertisement
Spotlight
  • 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
  • CancerNetwork® Inaugural Face-Off
  • Contemporary Concepts in Hematologic Oncology
  • Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
  • Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
  • Real-World Evidence in NSCLC Guides Clinical Decisions
  • Targeting NSCLC with Uncommon EGFR Mutations
ClinicalSee All >
  • Acute Myeloid Leukemia
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Hematology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Pediatric Cancers
  • Skin Cancer
  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.

Using Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

Joshua Richter, MD, discusses the evolving treatment landscape in relapsed/refractory multiple myeloma.

EP. 1: Overview of Multiple Myeloma and Treatment Options

January 20th 2023

Joshua Richter, MD, gives an overview of treatment options in multiple myeloma and factors that influence treatment decisions.

EP. 2: Role of Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

January 20th 2023

Expert oncologist Joshua Richter, MD, defines triple-class refractory multiple myeloma and describes selinexor’s unique mechanism of action.

EP. 3: Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple-Class Refractory MM

January 27th 2023

An overview of recent data on selinexor, carfilzomib, and dexamethasone in triple-class refractory multiple myeloma, and treatment options to replace belantamab.

EP. 4: Bispecific Antibodies in the Treatment of Multiple Myeloma

January 27th 2023

An expert oncologist evaluates the effect of combination trials of bispecific antibodies on the multiple myeloma treatment landscape.

EP. 5: Clinical Pearls and Unmet Needs in R/R Multiple Myeloma

February 3rd 2023

Joshua Richter, MD, offers advice to community oncologists and discusses unmet needs in the treatment of patients with relapsed/refractory MM.

Advertisement
Advertisement